PE20081105A1 - SAL DE LA 5-AMINO-3-(2'-O-ACETIL-3'-(DESOXI-BETA-D-RIBOFURANOSIL)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO Y METODOS PARA SU PREPARACION - Google Patents

SAL DE LA 5-AMINO-3-(2'-O-ACETIL-3'-(DESOXI-BETA-D-RIBOFURANOSIL)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO Y METODOS PARA SU PREPARACION

Info

Publication number
PE20081105A1
PE20081105A1 PE2007001399A PE2007001399A PE20081105A1 PE 20081105 A1 PE20081105 A1 PE 20081105A1 PE 2007001399 A PE2007001399 A PE 2007001399A PE 2007001399 A PE2007001399 A PE 2007001399A PE 20081105 A1 PE20081105 A1 PE 20081105A1
Authority
PE
Peru
Prior art keywords
desoxi
ona
thiazol
pyrimidin
acetyl
Prior art date
Application number
PE2007001399A
Other languages
English (en)
Inventor
David Kucera
Gregory J Haley
Erik J Rueden
Tingman Wang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of PE20081105A1 publication Critical patent/PE20081105A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO 5-AMINO-3-(2'-O-ACETIL-3-(DESOXI-BETA-D-RIBOFURANSOLI)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO; CARACTERIZADO PORQUE ESENCIALMENTE ESTA LIBRE DE SOLVENTE RESIDUAL. DICHO COMPUESTO ESTA EN FORMA CRISTALINA CARACTERIZADA POR UNA DIFRACCION DE RAYOS X (2-TETA) CON LA LINEA MAS FUERTE OBSERVADA A UN ANGULO DE 5,5 GRADOS +- 0.3 GRADOS CON LINEAS DE MENOR INTENSIDAD A 11.8, 12.3, 17.9, 18.2, 19.7, 20.2, 21.3, 21.9, 23.8, 24.1 Y 25.9 +-0.3 Y SON UTILES EN EL TRATAMIENTO DE HEPATITIS B, HEPATITIS C, TUMOR, CANCER, ENTRE OTROS
PE2007001399A 2006-10-17 2007-10-16 SAL DE LA 5-AMINO-3-(2'-O-ACETIL-3'-(DESOXI-BETA-D-RIBOFURANOSIL)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO Y METODOS PARA SU PREPARACION PE20081105A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02

Publications (1)

Publication Number Publication Date
PE20081105A1 true PE20081105A1 (es) 2008-08-15

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001399A PE20081105A1 (es) 2006-10-17 2007-10-16 SAL DE LA 5-AMINO-3-(2'-O-ACETIL-3'-(DESOXI-BETA-D-RIBOFURANOSIL)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO Y METODOS PARA SU PREPARACION

Country Status (25)

Country Link
US (2) US7928085B2 (es)
EP (1) EP2076132B1 (es)
JP (2) JP5279715B2 (es)
KR (2) KR101515077B1 (es)
AR (1) AR063484A1 (es)
AU (1) AU2007353381B2 (es)
BR (1) BRPI0717741A2 (es)
CA (2) CA2666537C (es)
CY (1) CY1113368T1 (es)
DK (1) DK2076132T3 (es)
DO (1) DOP2007000131A (es)
EA (1) EA017005B1 (es)
ES (1) ES2390930T3 (es)
HK (1) HK1132429A1 (es)
IL (2) IL198180A (es)
MX (1) MX2009004028A (es)
MY (1) MY150408A (es)
NO (1) NO20091598L (es)
NZ (1) NZ576408A (es)
PE (1) PE20081105A1 (es)
PL (1) PL2076132T3 (es)
PT (1) PT2076132E (es)
TW (1) TWI415854B (es)
UY (1) UY30650A1 (es)
WO (1) WO2008140549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345527B2 (ja) 2006-06-22 2013-11-20 アナディス ファーマシューティカルズ インク プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン
WO2009026292A1 (en) * 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
HUE053704T2 (hu) 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
KR102139708B1 (ko) 2015-03-16 2020-07-31 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
JP6779232B2 (ja) 2015-05-08 2020-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
EP3317289B1 (en) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
WO2018127525A1 (en) * 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 １―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc ２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
DE60234376D1 (de) * 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
BRPI0414045A (pt) * 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
WO2005121162A1 (en) * 2004-06-07 2005-12-22 Anadys Pharmaceuticals, Inc. 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
US7560544B2 (en) * 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
JP5345527B2 (ja) * 2006-06-22 2013-11-20 アナディス ファーマシューティカルズ インク プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン
WO2008069303A1 (ja) * 2006-12-08 2008-06-12 Api Corporation フラノース誘導体の製造方法

Also Published As

Publication number Publication date
US8193342B2 (en) 2012-06-05
IL223126A (en) 2016-08-31
AU2007353381A1 (en) 2008-11-20
MY150408A (en) 2014-01-15
DK2076132T3 (da) 2012-09-10
KR20090074237A (ko) 2009-07-06
ES2390930T3 (es) 2012-11-19
CA2666537C (en) 2015-12-08
EP2076132B1 (en) 2012-07-11
TW200833699A (en) 2008-08-16
KR101486444B1 (ko) 2015-01-26
US20090197826A1 (en) 2009-08-06
IL223126A0 (en) 2012-12-31
HK1132429A1 (es) 2010-02-26
EA200970387A1 (ru) 2009-10-30
MX2009004028A (es) 2009-05-11
UY30650A1 (es) 2008-05-31
IL198180A0 (en) 2009-12-24
BRPI0717741A2 (pt) 2014-04-08
JP5703334B2 (ja) 2015-04-15
PT2076132E (pt) 2012-10-03
US7928085B2 (en) 2011-04-19
CA2666537A1 (en) 2008-11-20
JP5279715B2 (ja) 2013-09-04
CA2898225A1 (en) 2008-11-20
WO2008140549A1 (en) 2008-11-20
NO20091598L (no) 2009-07-10
AR063484A1 (es) 2009-01-28
EP2076132A4 (en) 2011-05-04
US20110172447A1 (en) 2011-07-14
CY1113368T1 (el) 2016-06-22
JP2013166782A (ja) 2013-08-29
NZ576408A (en) 2012-04-27
EP2076132A1 (en) 2009-07-08
IL198180A (en) 2015-06-30
KR101515077B1 (ko) 2015-04-24
JP2010506947A (ja) 2010-03-04
KR20140119203A (ko) 2014-10-08
DOP2007000131A (es) 2008-09-15
TWI415854B (zh) 2013-11-21
AU2007353381B2 (en) 2013-07-04
EA017005B1 (ru) 2012-09-28
PL2076132T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
PE20081105A1 (es) SAL DE LA 5-AMINO-3-(2'-O-ACETIL-3'-(DESOXI-BETA-D-RIBOFURANOSIL)-3H-TIAZOL[4,5-d]PIRIMIDIN-2-ONA DEL ACIDO P-TOLUENSULFONICO Y METODOS PARA SU PREPARACION
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
CO6640297A2 (es) Pirazolo[1,5-a] pirimidinas como agentes antivirales
BR112013009093A2 (pt) dispersões sólidas contendo um agente indutor de apoptose
EA201690994A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
NZ595382A (en) Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX351670B (es) Bacteria bacillus para uso en tratar y prevenir infecciones en animales acuaticos.
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
GT200500360A (es) Compuestos organicos
BRPI0720178A2 (pt) Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
CL2007003584A1 (es) Alimento para animales que utiliza krill como toda o parte de una fuente de proteina del alimento que comprende que se usa krill sin caparazon; y metodo para minimizar la reduccion en la tasa de crecimiento de los peces causada por el uso del krill c
UY33719A (es) Derivados de 2,3-dihidroimidazo [1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
PE20071016A1 (es) Formas cristalinas de n-(benzo[b]tien-3-ilmetil)-sulfamida
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2010001115S1 (es) Estanque de inodoro constituido basicamente por un cuerpo prismatico de seccion transversal rectangular de vertices frontales circunferenciales y vertices posteriores redondeados, que disminuye longitudinal y lateralmente su area de ariba hacia abajo.
CR10199A (es) Derivados de benzimidazol
ATE543492T1 (de) Behandlung von lungenkrebs
BRPI1014174A2 (pt) uso de um composto da fórmula (i),(ii),(iii), ou (iv) ou um sal farmaceuticamente aceitável seu para a fabricação de um medicamento para o tratamento de câncer em um humano ou um animal; método para o tratamento de câncer, pacote comercial, método para redução de células cancerosas e kit para o tratamento de câncer

Legal Events

Date Code Title Description
FD Application declared void or lapsed